study on anticancer activity of 4, 4’-[1,4-phenylenebis(1,3,4-thiadiazole-5,2-diyl)] bis(azaneylylidene) bis(methaneylylidene) diphenolon breast cancer cells

New medicinal compounds are being evaluated due to the increasing prevalence of cancer in human societies and the necessity to produce new medications for treatment. the new schiff base compound 4,4'-[1,4-phenylenebis(1,3,4-thiadiazole-5,2-diyl)] bis (azaneylylidene) bis (methaneylylidene) diphenol, which was previously produced from the reaction of 5,5' [(1,4-phenelene) bis (1,3,4-thiadiazol-2-amine)] and the para-hydroxy ben aldehyde was synthesized and different concentrations (250 and 300 mg/ml) of this new compound were exposed to breast cancer (mcf-7) cells to examine its cytotoxicity effect. cell line viability, acridine orange/propidium iodide staining, and dna fragmentation were assessed in evaluating the antitumor effect of the new composition. obtained data from cell viability assays demonstrated cytotoxic activity against mcf-7 breast cancer cell lines. no fragmentation was observed in dna fragmentation of the novel compound base with mcf-7 and vero cell line. the new schiff base compound indicated well-defined anti-cancer activity when treated with breast cancer cells (mcf-7). the compound blocked the proliferation of cancer cells without apoptosis. as a consequence of the findings, it was recommended to use this compound in treating breast cancer.